| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7625884 | VALEANT PHARMS INTL | Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives |
Aug, 2026
(2 years from now) | |
| US7452872 | VALEANT PHARMS INTL | Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives |
Aug, 2026
(2 years from now) | |
|
US7452872 (Pediatric) | VALEANT PHARMS INTL | Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives |
Feb, 2027
(2 years from now) | |
|
US7625884 (Pediatric) | VALEANT PHARMS INTL | Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives |
Feb, 2027
(2 years from now) | |
Colazal is owned by Valeant Pharms Intl.
Colazal contains Balsalazide Disodium.
Colazal has a total of 4 drug patents out of which 0 drug patents have expired.
Colazal was authorised for market use on 18 July, 2000.
Colazal is available in capsule;oral dosage forms.
Colazal can be used as treatment of ulcerative colitis.
The generics of Colazal are possible to be released after 24 February, 2027.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Pediatric Exclusivity(PED) | Jun 20, 2014 |
| Orphan Drug Exclusivity(ODE) | Dec 20, 2013 |
Drugs and Companies using BALSALAZIDE DISODIUM ingredient
Market Authorisation Date: 18 July, 2000
Treatment: Treatment of ulcerative colitis
Dosage: CAPSULE;ORAL
How can I launch a generic of COLAZAL before it's drug patent expiration?
More Information on Dosage
COLAZAL family patents
